These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 17189096

  • 1. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G.
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [Abstract] [Full Text] [Related]

  • 2. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D.
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [Abstract] [Full Text] [Related]

  • 3. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
    Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, Perroncel R.
    Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
    [Abstract] [Full Text] [Related]

  • 4. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I, Gogos CA, Bassaris H.
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [Abstract] [Full Text] [Related]

  • 5. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J, Ariza H, Jardim JR, Caballero A, García-Calderón A, Amábile-Cuevas CF, Hernández-Oliva G, Vivar-Orozco R, MOX-CB Study Group.
    Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S.
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA, Sinusitis Study Group.
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [Abstract] [Full Text] [Related]

  • 13. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR, Pressler T, Hoiby N, Johansen HK.
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Cazzola M, Vinciguerra A, Di Perna F, Califano C, Calderaro F, Salzillo A, Centanni S.
    J Chemother; 1999 Apr; 11(2):119-25. PubMed ID: 10326742
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical experience with moxifloxacin in patients with respiratory tract infections.
    Faich GA, Morganroth J, Whitehouse AB, Brar JS, Arcuri P, Kowalsky SF, Haverstock DC, Celesk RA, Church DA.
    Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA, Mösges R, Desrosiers M, Haverstock D, van Veenhuyzen D, Herman-Gnjidic Z.
    Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.